The trial is a prospective, one armed, single center phase I/II study investigating a combination of neoadjuvant dose-escalated IMRT (50???56???Gy) followed by surgery and IORT (10???12???Gy) in patients with at least marginally resectable RSTS. The primary objective is the local control rate after five years.